• This study has some limitations First the immunoblot

  2019-11-06

  

  This study has some limitations. First, the immunoblot analyses performed in the present study did not test for whole retinal antigens. Therefore, we could not exclude the possibility that the clinical features of our cases were caused by the activity of other antiretinal antibodies, although the sa

• Two primary members of the TRIM family TRIM

  2019-11-06

  

  Two primary members of the TRIM family – TRIM5α and TRIM25 – function as antiviral effector and immune regulator, respectively. TRIM5α is one of the best characterized members of the TRIM family (both structurally and functionally) and reported to be an important ubiquitin-mediated regulator of a ma

• In the Cu bioassay notwithstanding the absence of

  2019-11-06

  

  In the Cu bioassay, notwithstanding the absence of significant Cu bioaccumulation in bulk tissues over the 96-h exposure period (less than 2-fold difference in tissue Cu between controls and the second-highest treatment), T-ChE activity increased with Cu concentration in gill and, to a lesser extent

• br Author Contributions br Funding

  2019-11-06

  

  Author Contributions Funding Canadian Institutes of Health Research, operating grant NMD-83126 and the internal funding from the National Research Council Canada, Charlottetown, PE, Canada. Disclosure Statement Acknowledgements Introduction Cholesterol is an essential structural comp

• br Discussion The present results demonstrate that high

  2019-11-06

  

  Discussion The present results demonstrate that high dose estrogen–progestogen OC treatment produced impaired glucose tolerance and glucose tolerance was preserved during low dose estrogen–progestogen, high or low dose progestogen-only OC use. The study also shows that impaired glucose tolerance

• br Acknowledgements This study is sponsored by the Natural

  2019-11-06

  

  Acknowledgements This study is sponsored by the Natural Science Foundation of China (grant no. 51178161), 111 Project (grant no. B13024) and the Fundamental Research Funds for the Central Universities (grant no. 2017B00914) Introduction Highway and pavement engineers are facing concrete pavem

• In the present study we investigated the role

  2019-11-06

  

  In the present study, we investigated the role of EP1R after ICH and its mechanism of action. We hypothesized that EP1R activation aggravates ICH injury but that its blockade reduces injury through the Src kinases and the MMP-9 signaling pathway. To test this hypothesis, we examined the effects of

• The interface between the E ligase and

  2019-11-05

  

  The interface between the E3 ligase and the E2 enzyme can vary, and ZNF451 and SP-RING ligases stabilize this interaction via noncovalent binding to a scaffold SUMO (SUMOB) on the backside of the E2 (Cappadocia et al., 2015; Eisenhardt et al., 2015; Streich & Lima, 2016). By contrast, RanBP2 does no

• The BMP family comprises significant growth factors

  2019-11-05

  

  The BMP family comprises significant growth factors for the regeneration of bone and cartilage. Among these, BMP- has been known as an early marker during the proliferation of osteoblast cells, and one of the most potent stimulators of osteoblastic cells differentiation [40]. Studies with COX-2 knoc

• Our ex vivo analysis demonstrates that IL promotes CD

  2019-11-05

  

  Our ex vivo analysis demonstrates that IL-15 promotes CD122 expression in DGKζ-deficient CD8+ T cells. CD122, which forms a dimer with CD132 in response to IL-2 or IL-15, activates the JAK/STAT and PI3K/mTOR pathways. Whereas antigen-stimulated Arylquin 1 promote IL-2 sensitivity through up-regulat

• Some pyrimidine analogs are substrate based inhibitors that

  2019-11-05

  

  Some pyrimidine analogs are substrate-based inhibitors that bind to the dihydroorotate binding site, but most reported inhibitors of DHODH bind to the site occupied by the ubiquinone co-factor., , , , , , , , , , , , , , , , , X-ray crystallographic studies of inhibitor complexes with DHODH and DHOD

• Previous and ongoing clinical trials have been

  2019-11-05

  

  Previous and ongoing clinical trials have been summarized in a recent review (Siaw-Debrah et al., 2017). To our knowledge, there are no ongoing or completed clinical trials focusing on cytokines in ICH. Published studies have focused mainly on cytokine changes in ICH patients (summarized in Table 3)

• It is well known that

  2019-11-05

  

  It is well-known that corticotropin-releasing factor (CRF) exerts its biological functions through binding to type-1 (CRF1) and/or type-2 (CRF2) receptors. Several clinical evidences suggest the association of a high level of CRF and the onset of anxiety and depressive disorders.2, 3, 4, 5, 6, 7 Si

• Recently we have observed that pharmacological

  2019-11-05

  

  Recently, we have observed that pharmacological PPARα and PPARβ/δ activation regulates the expression of genes involved in FA metabolism such as FAT/CD36, CPT1, LCAD and MCAD in Sertoli cells. We have also observed that PPARβ/δ activation can simultaneously regulate the expression of the above-menti

• In glioblastoma methylation of pMGMT

  2019-11-05

  

  In glioblastoma, methylation of pMGMT is predictive of the efficacy of temozolomide with an increased survival [22], [23], [24], [25]. As in glioblastoma [24], [26], [27], [28], pMGMT methylation assessed by pyrosequencing (with immunochemistry, IHC) is the most effective and reproducible technique

14508 records 899/968 page Previous Next First page 上5页 896897898899900 下5页 Last page